Mr. Stephen Van Deventer reports

BIOGENE THERAPEUTICS INC. APPOINTS RAJ S. PRUTHI, MD, MHA, FACS, AS DIRECTOR

BioGene Therapeutics Inc., a company that Preveceutical Medical Inc. is a significant shareholder of, has appointed Dr. Raj S. Pruthi, MD, MHA, FACS, as a director of the company. Dr. Pruthi, a renowned physician-scientist, executive leader and board-level strategist with over two decades of experience in academic medicine, global pharmaceutical leadership and biotechnology innovation, will lead BioGene's clinical strategy and advance its innovative gene therapy programs targeting metabolic disorders such as diabetes and obesity.

Dr. Pruthi brings deep expertise in registrational clinical trial design and execution, global regulatory engagement (FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency)), capital markets strategy and cross-functional leadership. Most recently, as chief medical officer at Relmada Therapeutics Inc. since June, 2025, he has led the development of the NDV-011 program for bladder cancer, overseeing a phase 2 open-label study and preparations for a multinational phase 3 registrational trial set to begin in the first half of 2026. In this role, he managed KOL (key opinion leader) engagement, site recruitment, patient assessments and execution while also contributing to external engagements with investors, patient advocacy groups and regulatory bodies. Dr. Pruthi played a key role in a public offering that raised over $100-million in net proceeds, extending the company's cash runway into 2028, and, most recently, a PIPE (private investment in public equity) that raised an additional $160-million.

Prior to Relmada, Dr. Pruthi served as chief medical officer at enGene Inc. from April, 2024, to June, 2025, where he spearheaded a global gene therapy registrational program for bladder cancer across over 60 countries, including North America, Europe and APAC (Asia Pacific), with a planned BLA (biologics licence application) submission in 2026. He grew the medical and clinical development teams from five to nearly 20 members, managing a $32-million annual budget and overseeing CRO (contract research organization) performance.

From September, 2022, to April, 2024, Dr. Pruthi was senior global medical affairs leader for bladder cancer and senior medical director in oncology at Johnson & Johnson Innovative Medicine (Janssen), where he wrote three large phase 3 trials (400 to 500 patients each) for evidence generation and registrational purposes. He contributed to FDA and EMA approvals, including the FDA approval of TAR-200 in September, 2025, for BCG-unresponsive non-muscle invasive bladder cancer, and integrated patient-reported outcomes, digital health and remote monitoring into study designs.

Before his industry transition, Dr. Pruthi had a distinguished academic career from March, 2000, to September, 2022, serving as a tenured professor and department chair of urology at leading institutions, including the University of California, San Francisco (UCSF), and the University of North Carolina (UNC). He pioneered robotic surgical techniques, such as robotic radical cystectomy and intracorporeal urinary diversion, and performed them as a visiting professor in Europe, China and South Korea. His academic contributions include over 220 peer-reviewed publications, more than 20 book chapters, over 420 scientific presentations and leadership in national guideline development, including the AUA Bladder Cancer Guidelines Committee since 2004.

Dr. Pruthi has held numerous national leadership roles, including past president and president of the Society of Academic Urology, chair of the advisory council for urology at the American College of Surgeons, and chair of the AUA (American Urological Association) publications committee, and membership in prestigious societies such as the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons. He has been recognized with awards such as Best Doctors in America annually from 2013 to 2021, Castle Connolly's America's Top Doctors and multiple teaching excellence honours.

Committed to diversity, equity and inclusion (DEI), Dr. Pruthi has championed diverse leadership in urology, noting that, at UCSF, 25 per cent of faculty and 44 per cent of residents were female -- exceeding national averages. His efforts include health services research on racial disparities in cancer care and initiatives to increase opportunities for underrepresented minorities.

In education and mentorship, Dr. Pruthi has mentored residents, fellows and faculty, emphasizing personalized career development. At UCSF and UNC, he expanded residency programs, implemented innovative training tools such as app-based feedback and surgical simulations, and fostered a culture of faculty wellness and development, resulting in high satisfaction rates and successful graduate outcomes.

Dr. Pruthi earned his MD from Duke University School of Medicine, completed surgical and urology training at Stanford University, and holds a master of health administration from UNC Chapel Hill. He is board certified by the American Board of Urology and is a fellow of the American College of Surgeons.

"I am thrilled to join BioGene Therapeutics at this pivotal time in its growth," said Dr. Pruthi. "The company's focus on dual gene therapy for metabolic health aligns perfectly with my passion for innovative, patient-centred solutions. Drawing from my experience in leading global registrational trials, regulatory strategies and team building in gene therapy and oncology, I look forward to collaborating with the team to accelerate the company's clinical programs and deliver transformative therapies for diabetes and obesity, addressing unmet needs in preventive and curative medicine."

Stephen Van Deventer, chairman and chief executive officer of Preveceutical Medical, commented: "We are delighted to welcome Dr. Pruthi to BioGene Therapeutics. His proven track record in gene therapy, regulatory strategy, clinical trial execution and academic leadership will be instrumental as we advance our pipeline. Raj's expertise in scaling teams, securing funding and driving FDA approvals strengthens our leadership and positions BioGene for success in developing cutting-edge treatments that leverage nature and science for better health outcomes."

The company has granted 100,000 stock options to Dr. Pruthi, with each option exercisable into one common share of the company at an exercisable price of $5 per share until March 10, 2030. The company has also granted Dr. Pruthi 500,000 restricted share units. The options and the RSUs vest as to 25 per cent on March 10, 2026, 25 per cent on March 10, 2027, 25 per cent on March 10, 2028, and 25 per cent on March 10, 2029.

About Preveceutical Medical Inc.

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products. Preveceutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the sol-gel program; nature-identical peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

About BioGene Therapeutics Inc.

BioGene is a Texas-based life sciences company focused on advancing innovative therapies in metabolic health and gene-based treatments. As a key component of BioGene's expansion, BioGene Australia operates as a wholly owned subsidiary of BioGene in Texas, leveraging the strategic benefits of Australia's 43.5-per-cent R&D (research and development) tax cashback incentive. This subsidiary supports continuing research and development activities in Australia, where BioGene capitalizes on exceptional scientific talent and the nation's commitment to advancing life sciences. Currently, BioGene Australia is engaged in pioneering research into GLP-1 receptor agonists and advanced diabetes treatments, including gene therapies designed to address the growing global diabetes and obesity crisis.

We seek Safe Harbor.